Meeting
2024 ASCO Annual Meeting
Cost-effectiveness of single-day intravenous fosaprepitant versus three-day oral aprepitant anti-emetic regimen in pediatric patients receiving highly-emetogenic chemotherapy.
Authors
Manraj Singh Sra
All India Institute of Medical Science (AIIMS), New Delhi, India
Manraj Singh Sra , Azgar Abdul Rasheed , Shuvadeep Ganguly , Santosh Kumar , Priya Sharma , Ashwati S Pillai , Swetambri Sharma , DEEPAM PUSHPAM , Sameer Bakhshi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Symptom Management/Supportive Care/Palliative Care
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 10075)
DOI
10.1200/JCO.2024.42.16_suppl.10075
Abstract #
10075
Poster Bd #
442
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for prevention of emesis following highly emetogenic chemotherapy (HEC).
First Author: Eric Roeland
Poster
2021 ASCO Annual Meeting
Olanzapine or dexamethasone, with 5-HT3 receptor antagonist and NK-1 receptor antagonist, to prevent nausea and vomiting induced by cisplatin-based doublet chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial.
First Author: Zhigang Liu
Poster
2019 ASCO Annual Meeting
Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT).
First Author: Lee S. Schwartzberg